Literature DB >> 34090937

Hippocampal neurobiology and function in an aged mouse model of TDP-43 proteinopathy in an APP/PSEN1 background.

Sanaz Arezoumandan1, Xuezhu Cai2, Praveen Kalkarni2, Stephani A Davis1, Katherine Wilson1, Craig F Ferris2, Nigel J Cairns3, Michael A Gitcho4.   

Abstract

Aging is a major risk factor for Alzheimer's disease (AD), the most common cause of dementia worldwide. TDP-43 proteinopathy is reported to be associated with AD pathology is almost 50% of cases. Our exploratory study examined near end-stage (28 months old) mice selectively driving expression of human TDP-43 in the hippocampus and cortex in an APP/PSEN1 background. We hypothesized that hippocampal neuropathology caused by β-amyloidosis with TDP-43 proteinopathy induced in this model, resembling the pathology seen in AD cases, manifest with changes in resting state functional connectivity. In vivo magnetic resonance imaging and post-mortem histology were performed on four genotypes: wild type, APP/PSEN1, Camk2a/TDP-43, and Camk2a/TDP-43/APP/PSEN1. Our results revealed loss of functional coupling in hippocampus and amygdala that was associated with severe neuronal loss in dentate gyrus of Camk2a/TDP-43/APP/PSEN1 mice compared to APP/PSEN1 and wild type mice. The loss of cells was accompanied by high background of β-amyloid plaques with sparse phosphorylated TDP-43 pathology. The survival rate was also reduced in Camk2a/TDP-43/APP/PSEN1 mice compared to other groups. This end-of-life study provides exploratory data to reach a better understanding of the role of TDP-43 hippocampal neuropathology in diseases with co-pathologies of TDP-43 proteinopathy and β-amyloidosis such as AD and limbic predominant age-related TDP-43 encephalopathy (LATE).
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Limbic predominant age-related TDP-43 encephalopathy (LATE); Network connectivity; Resting state BOLD functional connectivity; TDP-43

Mesh:

Substances:

Year:  2021        PMID: 34090937      PMCID: PMC8237829          DOI: 10.1016/j.neulet.2021.136010

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.197


  65 in total

1.  How to defeat dementia.

Authors:  Elie Dolgin
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

2.  Early pathologic amyloid induces hypersynchrony of BOLD resting-state networks in transgenic mice and provides an early therapeutic window before amyloid plaque deposition.

Authors:  Disha Shah; Jelle Praet; Amira Latif Hernandez; Corinna Höfling; Cynthia Anckaerts; Frédérique Bard; Markus Morawski; Jan R Detrez; Els Prinsen; Alessandro Villa; Winnok H De Vos; Adriana Maggi; Rudi D'Hooge; Detlef Balschun; Steffen Rossner; Marleen Verhoye; Annemie Van der Linden
Journal:  Alzheimers Dement       Date:  2016-04-21       Impact factor: 21.566

Review 3.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

4.  Spontaneous Incidental Brain Lesions in C57BL/6J Mice.

Authors:  James C Tarrant; Patrick Savickas; Lorna Omodho; Marco Spinazzi; Enrico Radaelli
Journal:  Vet Pathol       Date:  2019-07-04       Impact factor: 2.221

Review 5.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

6.  Control of memory formation through regulated expression of a CaMKII transgene.

Authors:  M Mayford; M E Bach; Y Y Huang; L Wang; R D Hawkins; E R Kandel
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

Review 7.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.

Authors:  Kunihiro Uryu; Hanae Nakashima-Yasuda; Mark S Forman; Linda K Kwong; Christopher M Clark; Murray Grossman; Bruce L Miller; Hans A Kretzschmar; Virginia M-Y Lee; John Q Trojanowski; Manuela Neumann
Journal:  J Neuropathol Exp Neurol       Date:  2008-06       Impact factor: 3.685

9.  Resting state FMRI reveals diminished functional connectivity in a mouse model of amyloidosis.

Authors:  Disha Shah; Elisabeth Jonckers; Jelle Praet; Greetje Vanhoutte; Rafael Delgado Y Palacios; Christian Bigot; Dany V D'Souza; Marleen Verhoye; Annemie Van der Linden
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

10.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.

Authors:  Peter T Nelson; Dennis W Dickson; John Q Trojanowski; Clifford R Jack; Patricia A Boyle; Konstantinos Arfanakis; Rosa Rademakers; Irina Alafuzoff; Johannes Attems; Carol Brayne; Ian T S Coyle-Gilchrist; Helena C Chui; David W Fardo; Margaret E Flanagan; Glenda Halliday; Suvi R K Hokkanen; Sally Hunter; Gregory A Jicha; Yuriko Katsumata; Claudia H Kawas; C Dirk Keene; Gabor G Kovacs; Walter A Kukull; Allan I Levey; Nazanin Makkinejad; Thomas J Montine; Shigeo Murayama; Melissa E Murray; Sukriti Nag; Robert A Rissman; William W Seeley; Reisa A Sperling; Charles L White; Lei Yu; Julie A Schneider
Journal:  Brain       Date:  2019-06-01       Impact factor: 15.255

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.